Why is "Dystrophin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-08 02:10:12
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Dystrophin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-08 and was most recently seen on 2026-08-08.
Wikipedia Overview
Dystrophin is a rod-shaped cytoplasmic protein, and a vital part of a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane. This complex is variously known as the costamere or the dystrophin-associated protein complex (DAPC). Many muscle proteins, such as α-dystrobrevin, syncoilin, synemin, sarcoglycan, dystroglycan, and sarcospan, colocalize with dystrophin at the costamere. It has a molecular weight of 427 kDa.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Tevard Biosciences Announces Publication of Preclinical Research Supporting Engineered Suppressor tRNAs for Duchenne Muscular Dystrophy - TMX Newsfile
-
Muscle-targeted extracellular vesicles for full-length dystrophin mRNA therapy in Duchenne muscular dystrophy - Nature
-
Nivudirsen Increases Dystrophin Expression in Phase 1/2 Interim Study of DMD Amenable to Exon 51 Skipping - NeurologyLive
-
Dystrophin rescue in the brain for DMD - ScienceDirect.com
-
Novel gene therapy platform shows promise in Duchenne muscular dystrophy preclinical model - RegMedNet
-
FDA Clears ARCUS Editor for Duchenne Hot-spot - CRISPR Medicine News
-
Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD - Business Wire
-
FDA set to decide on experimental DMD treatment in early 2027 - Muscular Dystrophy News
-
Dystrophin-Deficient Cardiomyopathy Due to a Novel Hemizygous DMD Indel Variant: - JACC Journals
-
New mRNA Delivery Platform Restores Muscle Function in DMD Models - Genetic Engineering and Biotechnology News
-
Spot Biosystems Delivers Full-Length Dystrophin - AllSci
-
Intrinsic dysfunction in muscle stem cells lacking dystrophin begins during secondary myogenesis - Nature
-
WVE-N531 Shows Sustained Dystrophin Production in Phase 2 Trial of Duchenne Muscular Dystrophy - NeurologyLive
-
Dual-Vector Editing Maintains Year-Long Function for DMD - CRISPR Medicine News
-
Elevidys for Duchenne muscular dystrophy - Muscular Dystrophy News
-
Impact of dystrophin deficiency on vascular smooth muscle cell - Nature
-
Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy - NeurologyLive
-
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study - BioSpace
-
Tevard Biosciences Presents Preclinical Data Showing Complete Dystrophin Restoration and Robust Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026 - TMX Newsfile
-
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Precision BioSciences
-
Can Viltolarsen Treat Duchenne Muscular Dystrophy? - Docwire News
-
Spot Bio Launches With $40m And First Non-Viral Delivery of Full-Length Dystrophin - insights.citeline.com
-
Gene therapy delivery platform powers Spot Biosystems to $40M raise - FirstWord PHARMA
-
Trial testing gene-editing therapy PBGENE-DMD gets FDA green light - Muscular Dystrophy News
-
Entrada’s ENTR-601-44 Shows Efficacy, But Dystrophin Raises Questions - insights.citeline.com
-
Dyne Therapeutics’ Exon Skipping Duchenne Therapy Delivers Good Results - Inside Precision Medicine
-
Dyne, citing positive trial data, to ask FDA to approve DMD therapy - Muscular Dystrophy News
-
Letter to the Duchenne Community - Solid Biosciences
-
Update: Spot Bio launches with $40M to study non-viral gene therapy for muscular dystrophy - Endpoints News
-
Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy - Nature
-
3-drug cocktail boosts DMD gene therapy effectiveness in mice - Muscular Dystrophy News
-
Current Trends in Duchenne Muscular Dystrophy Research and Therapy: 3D Cardiac Modelling - Wiley Online Library
-
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
-
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice - Nature
-
The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction - Nature
-
Structure and assembly of the dystrophin glycoprotein complex - Nature
-
Spot Biosystems Launches with $40 Million Funding and Breakthrough Non-Viral Gene Therapy for DMD - bio-itworld.com
-
Evolution and developmental functions of the dystrophin-associated protein complex: beyond the idea of a muscle-specific cell adhesion complex - Frontiers
-
Dyne readies FDA push after DMD exon 51 med excels in trial - fiercebiotech.com
-
Full-length human dystrophin on human artificial chromosome compensates for mouse dystrophin deficiency in a Duchenne muscular dystrophy mouse model - Nature
-
Does DMD start in the womb? New research challenges old beliefs. - Muscular Dystrophy News
-
Entrada’s stock drops as DMD drug’s efficacy falls short - Clinical Trials Arena
-
Entrada Reports Early Functional Benefit in Phase 1/2 Duchenne Study of ENTR-601-44 - BioPharm International
-
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial - Nature
-
New Phase 3 SAFARI44 Trial To Confirm Benefit of Del-Zota in Duchenne Muscular Dystrophy - NeurologyLive
-
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model - Nature
-
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress - Sarepta Therapeutics
-
Neuronal hyperexcitability in dystrophin-deficient mdx hippocampal neurons: the importance of interleukin-6 and GABAergic regulation - Nature
-
Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division - Nature
-
Investigations of an inducible intact dystrophin gene excision system in cardiac and skeletal muscle in vivo - Nature
-
SonoThera™ Presents New Data at ESGCT 2025 Demonstrating Expression of Full-Length Human Dystrophin Using Targeted, Ultrasound-Mediated Delivery to Treat Duchenne Muscular Dystrophy - Business Wire
-
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy - Nature
-
In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse - Nature
-
Duchenne MD therapy brogidirsen shows long-term benefit in boys - Muscular Dystrophy News
-
Spot Biosystems Launches With $40 Million Financing and Early DMD Gene Therapy Results - citybiz
-
Dystrophin Immunity after Gene Therapy for Duchenne’s Muscular Dystrophy - NEJM
-
Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids - Nature
-
Understanding the Pathophysiology of Duchenne Muscular Dystrophy - NeurologyLive
-
Dystrophin/mini-dystrophin expression analysis by immunoaffinity liquid chromatography–tandem mass spectrometry after gene therapy for DMD - Nature
-
mRNA in situ hybridization exhibits unbalanced nuclear/cytoplasmic dystrophin transcript repartition in Duchenne myogenic cells and skeletal muscle biopsies | Scientific Reports - Nature
-
Novel mRNA platform improves muscle function in Duchenne muscular dystrophy - labmate-online.com
-
Dystrophin Immunity in Duchenne's Muscular Dystrophy - NEJM
-
Lentiviral vectors can be used for full-length dystrophin gene therapy - Nature
-
Enhanced expression of dystrophin, IGF-1, CD44 and MYH3 in plasma and skeletal muscles including diaphragm of mdx mice after oral administration of Neu REFIX beta 1,3-1,6 glucan - Nature
-
Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMD - Nature
-
Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation - Nature
-
In vivo restoration of dystrophin expression in mdx mice using intra-muscular and intra-arterial injections of hydrogel microsphere carriers of exon skipping antisense oligonucleotides - Nature
-
Utrophin Compensates dystrophin Loss during Mouse Spermatogenesis - Nature
-
Necroptosis mediates myofibre death in dystrophin-deficient mice - Nature
-
Dystrophin–glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation - Nature
-
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - 01net
-
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy - Science | AAAS
-
Evaluation of Safety Parameters and Dystrophin Expression by Sequential Administration of Exon-Skipping and Gene Therapy in a DMDmdx Mouse Model - Sarepta Therapeutics
-
Measuring Dystrophin in DMD | NeurologyLive - Clinical Neurology News and Neurology Expert Insights - NeurologyLive
-
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Clinical Trials Arena
-
DYNE-251 Increases Dystrophin Level Expression in Phase 1/2 DELIVER Trial of Duchenne - NeurologyLive
-
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin - Nature
-
Micro-Dystrophin in Gene Therapy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights - NeurologyLive
-
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications - Sarepta Therapeutics
-
Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model - Nature
-
Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material - Sarepta Therapeutics
-
Sarepta Therapeutics and Nationwide Children’s Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy - Sarepta Therapeutics
-
H19 lncRNA to dystrophin’s rescue - Nature
-
Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background - Nature
-
Del-zota increases dystrophin in DMD patients, new trial data show - Muscular Dystrophy News
-
Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy - Nature
-
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne - Sarepta Therapeutics
-
Engineered tRNA fixes faulty dystrophin protein in DMD mice - Muscular Dystrophy News
-
Human Dystrophin Dp71ab Enhances the Proliferation of Myoblasts Across Species But Not Human Nonmyoblast Cells - Frontiers
-
Del-Zota Produced Statistically Significant Increases in Exon-Skipping and Dystrophin Levels in EXPLORE44, a Phase 1/2 Study in Individuals With DMD44M - NeurologyLive
-
What to know about gene therapy for Duchenne muscular dystrophy - Medical News Today
-
Video: Dystrophin-deficient muscular dystrophy, dysphagia, dog (Brittany) - MSD Veterinary Manual
-
Dystrophin–glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling - PNAS
-
Simplest Possible Modification Rescues Dystrophin Expression in Duchenne - CRISPR Medicine News
-
The Critical Role of Dystrophin in the Pathophysiology of Duchenne Muscular Dystrophy - NeurologyLive
-
Chemical treatment enhances skipping of a mutated exon in the dystrophin gene - Nature
-
PPMD 2024: DMD therapies to boost dystrophin advance in trials - Muscular Dystrophy News
-
Resveratrol Ameliorates Mitophagy Disturbance and Improves Cardiac Pathophysiology of Dystrophin-deficient mdx Mice - Nature
-
Dystrophin deficiency reduces atherosclerotic plaque development in ApoE-null mice | Scientific Reports - Nature
-
Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy - Sarepta Therapeutics
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.